The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://elainetndq630152.blog2news.com/39412073/retatrutide-vs-tirzepatide-a-comparative-analysis